XML 94 R42.htm IDEA: XBRL DOCUMENT v3.25.4
Research Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 4 Months Ended 12 Months Ended
Sep. 30, 2021
Jul. 31, 2021
Nov. 30, 2017
Dec. 31, 2015
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2018
May 31, 2024
Apr. 30, 2024
Jun. 30, 2019
Dec. 31, 2017
Research Collaboration And License Agreements [Line Items]                        
Contract with customer, liability         $ 205.6 $ 448.2 $ 549.2          
Revenue, remaining performance obligation         205.6              
Contract revenue receivable if milestones achieved         3.5 7.8 9.4          
Common stock issued, net of issuance costs             370.2          
Collaboration contract asset and other assets         3.8 8.1            
Revenue         262.6 263.4 78.5          
Operating expenses         381.1 513.6 480.0          
Net loss         $ (80.8) $ (198.9) $ (367.3)          
Net loss per common share - basic (in dollars per share)         $ (1.14) $ (2.77) $ (6.62)          
Net loss per common share - diluted (in dollars per share)         $ (1.14) $ (2.77) $ (6.62)          
Updated Research Timelines                        
Research Collaboration And License Agreements [Line Items]                        
Revenue         $ (6.6) $ (2.4) $ (10.6)          
Net loss         $ 6.6 $ (2.4) $ (10.6)          
Net loss per common share - basic (in dollars per share)         $ 0.09 $ 0.03 $ 0.19          
Net loss per common share - diluted (in dollars per share)         $ 0.09 $ 0.03 $ 0.19          
Expansion of Development Programs                        
Research Collaboration And License Agreements [Line Items]                        
Revenue             $ (35.0)          
Net loss             $ (35.0)          
Net loss per common share - basic (in dollars per share)             $ 0.63          
Net loss per common share - diluted (in dollars per share)             $ 0.63          
Removal Of Combination Trials                        
Research Collaboration And License Agreements [Line Items]                        
Revenue         $ 150.2              
Operating expenses         2.6              
Net loss         $ 147.6              
Net loss per common share - basic (in dollars per share)         $ 2.08              
Net loss per common share - diluted (in dollars per share)         $ 2.08              
Common Shares                        
Research Collaboration And License Agreements [Line Items]                        
Common stock issued, net of issuance costs (in shares)             14,400,000          
Novartis Pharma AG | License                        
Research Collaboration And License Agreements [Line Items]                        
Contract with customer, liability                 $ 150.0      
Contingent payments                 $ 1,010.0      
Revenue recognized         $ 20.0              
Revenue, remaining performance obligation         130.0              
Capitalized costs                   $ 3.0    
Pfizer, Inc.                        
Research Collaboration And License Agreements [Line Items]                        
Payments received               $ 28.0        
Pfizer, Inc. | Collaboration Agreement                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   $ 650.0                    
Collaboration agreement direct and incremental costs incurred         12.9              
Collaboration contract asset and other assets         12.9              
Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   400.0                    
Pfizer, Inc. | Sales-based Milestones                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   1,000.0                    
Pfizer, Inc. | Stock Purchase Agreement                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   650.0                    
Fair value of the shares sold   85.4                    
Pfizer, Inc. | Stock Purchase Agreement | Common Shares                        
Research Collaboration And License Agreements [Line Items]                        
Common stock issued, net of issuance costs (in shares) 3,457,815                      
Share price, issued and sold (in usd per share) $ 101.22                      
Common stock issued, net of issuance costs $ 350.0                      
Financial advisor fees $ 4.6                      
Pfizer, Inc. | Maximum | Regulatory and Sales Based Milestones                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved   $ 1,400.0                    
Pfizer, Inc. | Maximum | Option Payments To License Agreement                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                       $ 3.8
Pfizer, Inc. | Maximum | Sales-based Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                       550.0
Pfizer, Inc. | Maximum | Development Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                       $ 225.0
Bayer                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                     $ 17.5  
Bayer | Research Funding Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved             $ 12.0          
Payments received             $ 1.5          
Bayer | Maximum | Sales-based Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                     490.0  
Bayer | Maximum | Development Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved                     $ 197.5  
Genentech                        
Research Collaboration And License Agreements [Line Items]                        
Payments received     $ 34.5 $ 11.0                
Genentech | Regulatory Milestone Related to Marketing Approvals                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved         52.5              
Genentech | Commercial Milestones                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved         60.0              
Genentech | Maximum | Development Milestone Payments                        
Research Collaboration And License Agreements [Line Items]                        
Contract revenue receivable if milestones achieved         $ 44.0